Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Mrdovic

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Journal of Thrombosis and Thrombolysis|September 11, 2007
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndromeJovan Perunicic, Nebojsa M Antonijevic, Predrag Miljic, et al.
Journal of Medical Biochemistry|March 31, 2017
Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial InfarctionMina Radosavljevic-Radovanovic, Nebojsa Radovanovic, Zorana Vasiljevic, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|March 10, 2018
Oxidative stress markers predict early left ventricular systolic dysfunction after acute myocardial infarction treated with primary percutaneous coronary interventionDubravka Rajic, Ivica Jeremic, Sanja Stankovic, et al.
Journal of Interventional Cardiology|February 5, 2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 17, 2014
Impact of platelet phenotype on myocardial infarctionZufar Gabbasov, Jan Sabo, Daniel Petrovic, et al.
Coronary Artery Disease|November 24, 2011
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Clinical Medicine|June 10, 2022
Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 EraRatko Lasica, Lazar Djukanovic, Igor Mrdovic, et al.
Clinical Biochemistry|March 8, 2012
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary interventionSanja Stankovic, Milika Asanin, Danijela Trifunovic, et al.
Clinical Laboratory|January 8, 2013
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary interventionSanja Stankovic, Milika Asanin, Danijela Trifunovic, et al.
Journal of Clinical Medicine|April 26, 2025
Prognostic Value of the RISK-PCI Score in Patients with Non-ST-Segment Elevation Acute Myocardial InfarctionAna Stanojkovic, Igor Mrdovic, Ivana Tosic, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Journal of Thrombosis and Thrombolysis|September 11, 2007
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndromeJovan Perunicic, Nebojsa M Antonijevic, Predrag Miljic, et al.
Journal of Medical Biochemistry|March 31, 2017
Usefulness of NT-proBNP in the Follow-Up of Patients after Myocardial InfarctionMina Radosavljevic-Radovanovic, Nebojsa Radovanovic, Zorana Vasiljevic, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|March 10, 2018
Oxidative stress markers predict early left ventricular systolic dysfunction after acute myocardial infarction treated with primary percutaneous coronary interventionDubravka Rajic, Ivica Jeremic, Sanja Stankovic, et al.
Journal of Interventional Cardiology|February 5, 2013
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 17, 2014
Impact of platelet phenotype on myocardial infarctionZufar Gabbasov, Jan Sabo, Daniel Petrovic, et al.
Coronary Artery Disease|November 24, 2011
Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trialIgor Mrdovic, Lidija Savic, Gordana Krljanac, et al.
Journal of Clinical Medicine|June 10, 2022
Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 EraRatko Lasica, Lazar Djukanovic, Igor Mrdovic, et al.
Clinical Biochemistry|March 8, 2012
Time-dependent changes of myeloperoxidase in relation to in-hospital mortality in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary interventionSanja Stankovic, Milika Asanin, Danijela Trifunovic, et al.
Clinical Laboratory|January 8, 2013
Utility of lipoprotein-associated phospholipase A2 for prediction of 30-day major adverse coronary event in patients with the first anterior ST-segment elevation myocardial infarction treated by primary percutaneous coronary interventionSanja Stankovic, Milika Asanin, Danijela Trifunovic, et al.
Journal of Clinical Medicine|April 26, 2025
Prognostic Value of the RISK-PCI Score in Patients with Non-ST-Segment Elevation Acute Myocardial InfarctionAna Stanojkovic, Igor Mrdovic, Ivana Tosic, et al.
Pageof 5